Biodistribution and Clearance of Small Molecule Hapten Chelates for Pretargeted Radioimmunotherapy
- 9 June 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in Molecular Imaging & Biology
- Vol. 13 (2), 215-221
- https://doi.org/10.1007/s11307-010-0353-6
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- A modular IgG-scFv bispecific antibody topologyProtein Engineering, Design and Selection, 2009
- 177Lu- labeled MOv18 as compared to 131I- or 90Y-labeled MOv18 has the better therapeutic effect in eradication of alpha folate receptor-expressing tumor xenograftsNuclear Medicine and Biology, 2009
- A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinationsBlood, 2009
- Pretargeted Versus Directly Targeted Radioimmunotherapy Combined with Anti-CD20 Antibody Consolidation Therapy of Non-Hodgkin LymphomaJournal of Nuclear Medicine, 2009
- Synthesis and Evaluation of Technetium-99m- and Rhenium-Labeled Inhibitors of the Prostate-Specific Membrane Antigen (PSMA)Journal of Medicinal Chemistry, 2008
- Production of Multimeric Prostate-Specific Membrane Antigen Small-Molecule Radiotracers Using a Solid-Phase 99mTc Preloading StrategyJournal of Nuclear Medicine, 2007
- Cardiovascular Safety of Gadoterate Meglumine (Gd-DOTA)Investigative Radiology, 2007
- An HPLC/mass spectrometry platform for the development of multimodality contrast agents and targeted therapeutics: prostate‐specific membrane antigen small molecule derivativesContrast Media & Molecular Imaging, 2006
- Mitigation of radiation nephropathy after internal α-particle irradiation of kidneysInternational Journal of Radiation Oncology*Biology*Physics, 2006
- Differences in Biodistribution Between 99mTc-Depreotide, 111In-DTPA-Octreotide, and 177Lu-DOTA-Tyr3-Octreotate in a Small Cell Lung Cancer Animal ModelCancer Biotherapy & Radiopharmaceuticals, 2005